Ticker brief
BNTX BIONTECH SE-ADR
Consumer, Non-cyclical · Biotechnology
last close
$88.11
1 day
-1.7%
14 days
-9.1%
mkt cap
$24.7B
signals 14d
22
authors 14d
17
crowd 14d
-2.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 55% rich · 95 pctile own 1y | IV/HV 1.42× (as of 2026-10-22) |
| Skew — 25Δ RR 30d | +0.088 99 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.02 normal | 5-session Δ -0.01 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-03-11 (z=3.4) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-14 · now -0.60 (−1 bearish … +1 bullish)
Who spoke17
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Biotech2k1 | A | +1.11 | 4 | -0.77 |
| @bioinvestor24 | A | -0.87 | 3 | -0.33 |
| @WallStDiaries | C | +0.67 | 1 | -0.20 |
| @AlertsAndNews | C | -3.92 | 1 | -0.15 |
| @MartyChargin | C | -0.56 | 1 | +0.35 |
| @CleaRank | C | -1.63 | 1 | -0.20 |
| @BiopharmIQ | B | · | 1 | +0.15 |
| @USAnt_IDEA | C | -0.64 | 1 | +0.35 |
| @CHItrader | B | -0.22 | 1 | -0.70 |
| @BioStocks | C | -1.77 | 1 | -0.70 |
| @HammerstoneMar3 | C | +0.30 | 1 | -0.55 |
| @newsinvesting | C | · | 1 | -0.55 |
| @UTEX_io | C | +0.04 | 1 | -0.50 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @AponiaAnalytics | B | -1.06 | 1 | -0.60 |
| @alexkoh | B | -1.37 | 1 | -0.55 |
| @fwpharma | B | -1.91 | 1 | -0.60 |
Recent signals22of 22 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @fwpharma | -0.60 | BioNTech's HPV-targeted cancer vaccine missed its progression-free-survival goal. | -0.6% | tweet ↗ |
| 2026-10-13 | @alexkoh | -0.55 | BioNTech's AHEAD-MERIT trial missed its first primary endpoint, though monitoring continues. | -1.0% | tweet ↗ |
| 2026-10-13 | @AponiaAnalytics | -0.60 | BNT113's Phase 2/3 trial missed its PFS endpoint with no significant added benefit. | -1.0% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | -0.75 | Argues personalized cancer vaccines repeatedly fail outside melanoma. | -1.0% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | -0.75 | Argues personalized cancer vaccines fail commercially despite appealing science. | -1.0% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | -0.70 | Argues MRNA's rebound ignores that its technology should produce BNTX-like failures. | -1.0% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.00 | BioNTech issued an update on its Phase 2/3 BNT113 cancer-immunotherapy trial. | -1.0% | tweet ↗ |
| 2026-10-13 | @UTEX_io | -0.50 | Multi-company mover roundup reports earnings, guidance, analyst actions and a failed BNTX trial. | -1.0% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | -0.90 | Argues BNTX's result confirms longstanding skepticism that this cancer-vaccine approach works broadly. | -1.0% | tweet ↗ |
| 2026-10-13 | @newsinvesting | -0.55 | BioNTech's experimental cancer drug missed its first major trial endpoint, though another endpoint remains pending. | -1.0% | tweet ↗ |
| 2026-10-13 | @HammerstoneMar3 | -0.55 | BioNTech's BNT113 phase 2/3 trial missed its first dual primary endpoint; both stocks fell premarket. | -1.0% | tweet ↗ |
| 2026-10-13 | @BioStocks | -0.70 | BioNTech's Phase 2/3 AHEAD-MERIT trial missed its first dual primary PFS endpoint. | -1.0% | tweet ↗ |
| 2026-10-13 | @CHItrader | -0.70 | BioNTech's BNT113 combination failed the Phase 2/3 progression-free-survival endpoint. | -1.0% | tweet ↗ |
| 2026-10-12 | @USAnt_IDEA | +0.35 | Links Moderna's 600% rally to cancer-vaccine news, index inclusion and sector-wide momentum, while noting trial risk. | -8.1% | tweet ↗ |
| 2026-10-10 | @bioinvestor24 | -0.20 | Argues Moderna perfected immunogenic-epitope prediction while BioNTech acquired comparable capabilities. | -9.1% | tweet ↗ |
| 2026-10-10 | @bioinvestor24 | -0.35 | Sees explosive upside if Moderna's efficacy is strong, while criticizing BioNTech's platform and Merck's execution. | -9.1% | tweet ↗ |
| 2026-10-10 | @BiopharmIQ | +0.15 | Weekly biotech roundup summarizes mixed clinical, commercial, and pipeline developments. | -9.1% | tweet ↗ |
| 2026-10-10 | @CleaRank | -0.20 | Reports the CEO selling 63,209 shares while retaining a large indirect holding. | -9.1% | tweet ↗ |
| 2026-10-09 | @MartyChargin | +0.35 | NYT reports cancer vaccines could receive accelerated NIH treatment. | -9.1% | tweet ↗ |
| 2026-10-09 | @bioinvestor24 | -0.45 | Forecasts remarkable MRNA cancer-vaccine efficacy, broad indications and a durable lead over BNTX. | -9.1% | tweet ↗ |
| 2026-10-07 | @AlertsAndNews | -0.15 | A broad federal vaccine-injury research and reporting initiative is being launched. | -7.5% | tweet ↗ |
| 2026-10-04 | @WallStDiaries | -0.20 | Reports planned founder departures at BioNTech and warns about conflicts and governance trust. | -9.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.